Technologies and Resources for Core Laboratories

核心实验室的技术和资源

基本信息

  • 批准号:
    10213758
  • 负责人:
  • 金额:
    $ 43.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2022-06-30
  • 项目状态:
    已结题

项目摘要

The West Virginia Clinical and Translational Science Institute (WVCTSI) will establish a new key component area (Technology and Resources for Core Laboratories) that supports research infrastructure critical for translating basic research to practices that improve the health of West Virginians. Importantly, the Technology Core leverages previous IDeA investment in West Virginia, while bringing exciting innovation to support clinical and translational (C/T) investigators' efforts to solve meaningful problems. The Core is unique in its technology- based focus, but absolutely connected to the overarching aims of the WVCTSI that coalesce on improving health. Resources described in this Core are essential in providing infrastructure to engage and train C/T scientists about the value and availability of primary samples that define the gold standard in biologically-relevant disease models. In addition, we will develop contemporary approaches to data management of “omics” based information that inform our understanding of disease processes. Further, expanding models to include pre- clinical imaging will elevate C/T investigations to a level not previously attainable. Each focused effort will involve training, mentoring, and technical support that result in hands-on facilitation of investigations while maintaining strict quality control, and administrative and scientific oversight. Critically, this technology-grounded core will provide products and resources that are clinically applicable and translatable. The specific aims that will achieve our goals are to: 1) establish a statewide biospecimen repository that collects patient and study participant samples in WVCTSI priority health areas (addiction and resultant emerging epidemics (e.g., hepatitis C), cancer, cardiovascular disease, and chronic lung disease), 2) establish a statewide West Virginia University (WVU) - Marshall University (MU) genomics shared research facility for the efficient generation of genomic and related data for C/T studies that address WVCTSI priority health areas, 3) establish a statewide WVU-MU shared Bioinformatics and Data Management (BDM) Facility for C/T studies that address WVCTSI priority health areas, and 4) establish state-of-the-art imaging in support of biologically relevant modeling of disease. Focus across the Core is provided by tethering all activities to WVCTSI priority health areas to avoid diffusion of investment and energy, and maximize investment to achieve significant and measurable outcomes. Relevance is obtained by absolute diligence in the design and focus of each aim connecting to a clinical application. In combination, this results in impact on our understanding of specific diseases of interest, and the potential to impact positively on the health of West Virginians.
西弗吉尼亚州临床和转化科学研究所(WVCTSI)将建立一个新的关键组成部分, 核心实验室的技术和资源领域,支持研究基础设施, 将基础研究转化为改善西弗吉尼亚人健康的实践。重要的是,技术 Core利用之前在西弗吉尼亚州的IDEA投资,同时带来令人兴奋的创新,以支持临床 和翻译(C/T)研究人员的努力,以解决有意义的问题。核心的技术是独一无二的 这是一个基于重点的项目,但绝对与WVCTSI的总体目标有关,即改善健康。 本核心中描述的资源对于提供基础设施以吸引和培训C/T科学家至关重要 关于定义生物相关疾病金标准的原始样本的价值和可用性 模型此外,我们将开发基于“组学”的当代数据管理方法, 这些信息有助于我们理解疾病的过程。此外,扩大模型,包括前- 临床成像将把C/T研究提高到以前无法达到的水平。每一项重点工作将 包括培训、指导和技术支持,从而实际协助调查, 保持严格的质量控制,以及行政和科学监督。关键是,这种技术基础 核心将提供临床适用和可翻译的产品和资源。具体目标将 实现我们的目标是:1)建立一个全州范围的生物标本库,收集病人和研究 WVCTSI优先健康领域的参与者样本(成瘾和由此出现的流行病(例如,肝炎 C)、癌症、心血管疾病和慢性肺病),2)建立全州性的西弗吉尼亚大学 (WVU)- 马歇尔大学(MU)基因组学共享研究设施,用于高效生成基因组和 解决WVCTSI优先健康领域的C/T研究的相关数据,3)建立全州WVU-MU共享 生物信息学和数据管理(BDM)设施,用于针对WVCTSI优先卫生领域的C/T研究, 以及4)建立最先进的成像技术以支持疾病的生物学相关建模。焦点的 通过将所有活动与WVCTSI优先卫生领域联系起来,以避免投资分散,从而提供核心 和能源,并最大限度地投资,以实现重大和可衡量的成果。获得相关性 通过对与临床应用相关的每个目标的设计和重点的绝对勤奋。在组合中, 这将影响我们对感兴趣的特定疾病的理解, 西弗吉尼亚人的健康

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laura F. Gibson其他文献

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation
沙利度胺、来那度胺或硼替佐米诱导治疗的反应对接受自体移植的多发性骨髓瘤患者的结局的影响
  • DOI:
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    F. Awan;S. Osman;S. T. Kochuparambil;Laura F. Gibson;S. Remick;Jame Abraham;Michael Craig;Anand Jillella;Mehdi Hamadani
  • 通讯作者:
    Mehdi Hamadani
Prospective Evaluation of A ‘Two-Pronged’ Strategy of Atorvastatin Administration As Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis, to Both Donors and Recipients of Matched Related Donor (MRD) Allogeneic Hematopoietic Cell Transplantation (alloHCT)
  • DOI:
    10.1016/j.bbmt.2012.11.077
  • 发表时间:
    2013-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Mehdi Hamadani;Laura F. Gibson;Scot C. Remick;William Petros;Jame Abraham;Soumit Basu;William Tse;Aaron Cumpston;Pam Bunner;Michael Craig
  • 通讯作者:
    Michael Craig

Laura F. Gibson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laura F. Gibson', 18)}}的其他基金

Technologies and Resources for Core Laboratories
核心实验室的技术和资源
  • 批准号:
    10505670
  • 财政年份:
    2012
  • 资助金额:
    $ 43.32万
  • 项目类别:
Technologies and Resources for Core Laboratories
核心实验室的技术和资源
  • 批准号:
    10685612
  • 财政年份:
    2012
  • 资助金额:
    $ 43.32万
  • 项目类别:
CoBRE for Signal Transduction and Cancer Phase III
CoBRE 用于信号转导和癌症 III 期
  • 批准号:
    8116200
  • 财政年份:
    2011
  • 资助金额:
    $ 43.32万
  • 项目类别:
CoBRE for Signal Transduction and Cancer Phase III
CoBRE 用于信号转导和癌症 III 期
  • 批准号:
    8299627
  • 财政年份:
    2011
  • 资助金额:
    $ 43.32万
  • 项目类别:
CoBRE for Signal Transduction and Cancer Phase III
CoBRE 用于信号转导和癌症 III 期
  • 批准号:
    8710277
  • 财政年份:
    2011
  • 资助金额:
    $ 43.32万
  • 项目类别:
CoBRE for Signal Transduction and Cancer Phase III
CoBRE 用于信号转导和癌症 III 期
  • 批准号:
    8895998
  • 财政年份:
    2011
  • 资助金额:
    $ 43.32万
  • 项目类别:
CoBRE for Signal Transduction and Cancer Phase III
CoBRE 用于信号转导和癌症 III 期
  • 批准号:
    8509721
  • 财政年份:
    2011
  • 资助金额:
    $ 43.32万
  • 项目类别:
COBRE FOR SIGNAL TRANSDUCTION AND CANCER PHASE III
COBRE 用于信号转导和癌症 III 期
  • 批准号:
    8364913
  • 财政年份:
    2011
  • 资助金额:
    $ 43.32万
  • 项目类别:
COBRE: WVU: SIGNAL TRANSDUCTION & CANCER: ADMINISTRATIVE CORE
COBRE:西弗吉尼亚大学:信号传导
  • 批准号:
    8167955
  • 财政年份:
    2010
  • 资助金额:
    $ 43.32万
  • 项目类别:
The Role of the Stem Cell Niche in ALL
干细胞生态位在 ALL 中的作用
  • 批准号:
    8010156
  • 财政年份:
    2009
  • 资助金额:
    $ 43.32万
  • 项目类别:

相似海外基金

REU Site: Investigation of Subterranean Features in the Appalachian Region
REU 站点:阿巴拉契亚地区地下特征调查
  • 批准号:
    2149891
  • 财政年份:
    2022
  • 资助金额:
    $ 43.32万
  • 项目类别:
    Standard Grant
SRS RN: People-Centric Integrated Assessment Model for Regional Sustainability (PIAMRS): Focusing on the Central Appalachian Region
SRS RN:以人为本的区域可持续性综合评估模型(PIAMRS):重点关注阿巴拉契亚中部地区
  • 批准号:
    2115243
  • 财政年份:
    2022
  • 资助金额:
    $ 43.32万
  • 项目类别:
    Standard Grant
Developing and Evaluating Fraud Informatics Curriculum among Institutions in the Appalachian Region
开发和评估阿巴拉契亚地区机构之间的欺诈信息学课程
  • 批准号:
    1820609
  • 财政年份:
    2018
  • 资助金额:
    $ 43.32万
  • 项目类别:
    Standard Grant
Central Appalachian Region Educational Research Center
中央阿巴拉契亚地区教育研究中心
  • 批准号:
    9538521
  • 财政年份:
    2014
  • 资助金额:
    $ 43.32万
  • 项目类别:
Central Appalachian Region Educational Research Center
中央阿巴拉契亚地区教育研究中心
  • 批准号:
    9114878
  • 财政年份:
    2012
  • 资助金额:
    $ 43.32万
  • 项目类别:
Central Appalachian Region Educational Research Center
中央阿巴拉契亚地区教育研究中心
  • 批准号:
    9181014
  • 财政年份:
    2012
  • 资助金额:
    $ 43.32万
  • 项目类别:
Central Appalachian Region Educational Research Center
中央阿巴拉契亚地区教育研究中心
  • 批准号:
    8721630
  • 财政年份:
    2012
  • 资助金额:
    $ 43.32万
  • 项目类别:
Collaborative Research: Pleistocene-Holocene Climate Variability of the Southern Appalachian Region, Southeastern U.S.
合作研究:美国东南部阿巴拉契亚南部地区更新世-全新世气候变化
  • 批准号:
    0823131
  • 财政年份:
    2009
  • 资助金额:
    $ 43.32万
  • 项目类别:
    Standard Grant
Collaborative Research: Pleistocene-Holocene Climate Variability of the Southern Appalachian Region, Southeastern U.S.
合作研究:美国东南部阿巴拉契亚南部地区更新世-全新世气候变化
  • 批准号:
    0822824
  • 财政年份:
    2009
  • 资助金额:
    $ 43.32万
  • 项目类别:
    Standard Grant
Doctoral Dissertation Research: Long-Term Reconstruction of Oak Mast in the Southern Appalachian Region
博士论文研究:阿巴拉契亚南部地区橡树桅杆的长期重建
  • 批准号:
    0000281
  • 财政年份:
    2000
  • 资助金额:
    $ 43.32万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了